These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 29526844)

  • 41. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
    Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
    [TBL] [Abstract][Full Text] [Related]  

  • 42. P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation.
    Galić E; Vrbanić L; Kapitanović S; Catela Ivković T; Petro D; Vuković I; Bsharat RS; Milicević Z; Vcev A; Mirat J
    Coll Antropol; 2013 Jun; 37(2):491-8. PubMed ID: 23940995
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Roles of microRNA-221/222 in type 2 diabetic patients with post-menopausal breast cancer.
    Li MY; Pan SR; Qiu AY
    Genet Mol Res; 2016 Jul; 15(2):. PubMed ID: 27420990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy.
    Zou HL; Wang Y; Gang Q; Zhang Y; Sun Y
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1159-1166. PubMed ID: 28382439
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of adenosine diphosphate mediated platelet responsiveness for the stability of platelet integrity in citrated whole blood under ex vivo conditions.
    Koessler J; Schwarz M; Weber K; Etzel J; Koessler A; Boeck M; Kobsar A
    PLoS One; 2017; 12(11):e0188193. PubMed ID: 29155852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Platelet functional and transcriptional changes induced by intralipid infusion.
    Beaulieu LM; Vitseva O; Tanriverdi K; Kucukural A; Mick E; Hamburg N; Vita J; Freedman JE
    Thromb Haemost; 2016 Jun; 115(6):1147-56. PubMed ID: 26940969
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relationships between serum lipids, platelet membrane fatty acid composition and platelet aggregation in type 2 diabetes mellitus.
    Rodier M; Colette C; Crastes de Paulet P; Crastes de Paulet A; Monnier L
    Diabete Metab; 1993; 19(6):560-5. PubMed ID: 8026607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduction of CTRP9, a novel anti-platelet adipokine, contributes to abnormal platelet activity in diabetic animals.
    Wang W; Lau WB; Wang Y; Ma X; Li R
    Cardiovasc Diabetol; 2016 Jan; 15():6. PubMed ID: 26754066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of exercise and exercise conditioning on blood platelet function.
    Davis RB; Boyd DG; McKinney ME; Jones CC
    Med Sci Sports Exerc; 1990 Feb; 22(1):49-53. PubMed ID: 2137551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
    Ueno M; Ferreiro JL; Tomasello SD; Tello-Montoliu A; Capodanno D; Seecheran N; Kodali M; Dharmashankar K; Desai B; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2011 Aug; 4(8):905-12. PubMed ID: 21851906
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
    Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA
    Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.
    Angiolillo DJ; Bernardo E; Sabaté M; Jimenez-Quevedo P; Costa MA; Palazuelos J; Hernández-Antolin R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Guzman LA; Bass TA; Macaya C; Fernandez-Ortiz A
    J Am Coll Cardiol; 2007 Oct; 50(16):1541-7. PubMed ID: 17936152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
    Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alteration of the platelet transcriptome in chronic kidney disease.
    Plé H; Maltais M; Corduan A; Rousseau G; Madore F; Provost P
    Thromb Haemost; 2012 Oct; 108(4):605-15. PubMed ID: 22836280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The STIB score: a simple clinical test to predict clopidogrel resistance.
    Legrand D; Barbato E; Chenu P; Magne J; Vrolix M; Wijns W; Legrand V;
    Acta Cardiol; 2015 Oct; 70(5):516-21. PubMed ID: 26567810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.
    Chyrchel B; Totoń-Żurańska J; Kruszelnicka O; Chyrchel M; Mielecki W; Kołton-Wróż M; Wołkow P; Surdacki A
    Platelets; 2015; 26(6):593-7. PubMed ID: 25350775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased platelet purinergic sensitivity in peripheral arterial disease--a pilot study.
    Braun OO; Jagroop A; Wang L; Mikhailidis DP; Burnstock G; Erlinge D
    Platelets; 2005 Aug; 16(5):261-7. PubMed ID: 16011976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention.
    Zhang JH; Wang J; Tang XF; Yao Y; Zhang Y; Ma YL; Xu B; Gao RL; Song L; Gao Z; Chen J; Wu Y; Yang YJ; Meng XM; Yuan JQ
    Platelets; 2016; 27(1):75-9. PubMed ID: 25901734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.